Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04085900
Other study ID # NPC-PRO-003
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2020
Est. completion date December 31, 2027

Study information

Verified date July 2023
Source Zhongshan People's Hospital, Guangdong, China
Contact Mingfang Ji, MD
Phone 86-760-89880417
Email jmftbh@sina.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.


Description:

Sample selection - Select communities of 20,000 to 40,000 populations in Zhongshan City and Wuzhou city as the investigators' fields. Participants recruitment - Subjects voluntarily attend this screening study Informed consent - Informed consent forms will be collected at the recruitment. Questionnaires. - Face-to-face interviews are conducted by well-trained investigators. Tests and follow up - At initial screening, all participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, P85-Ab et al. And in males, EBV-DNA will be tested. Based on EBNA1-IgA, VCA-IgA, participants will be stratified into high, moderate and low risk. Screening positive include P85-Ab positive, high or moderate risk of NPC or EBV DNA positive. The rest will be screening negative. - During the initial screening and following up, people with high risk or P85-Ab positive will refer to the diagnostic workup for NPC. Briefly, fiberoptic endoscopy and pathological biopsy will be performed by otorhinolaryngologists. - Screening positive people not diagnosed as nasopharyngeal carcinoma in the first year will be followed up annually. - EBV DNA single positive people will refer to the diagnostic workup for NPC in the third year of follow up. - The rest of the blood samples will be stored at the biobank of Zhongshan People's Hospital for further research. - All subjects will also be followed by record linkage to Cancer Register and Population Register.


Recruitment information / eligibility

Status Recruiting
Enrollment 40000
Est. completion date December 31, 2027
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 69 Years
Eligibility Inclusion Criteria: - Subject residents in Zhongshan City or Wuzhou City - Subject has no medical record of nasopharyngeal carcinoma - ECOG 0-2 - Subject is able to comprehend, sign, and date the written informed consent document to participate in the study. - Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study. Exclusion Criteria: - Subject has heavy cardiovascular, liver or kidney disease. - Subject has contraindications to nasopharyngeal fiberoptic endoscopy.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Blood and saliva
Collect blood and saliva samples from participants
Diagnostic Test:
P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA
Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.
Fiberoptic endoscopy and biopsy
Screening participants will refer to fiberoptic endoscopy and biospy

Locations

Country Name City State
China Wuzhou Red Cross Hospital Wuzhou Guangxi
China Zhongshan People's Hospital Zhongshan Guangdong

Sponsors (3)

Lead Sponsor Collaborator
Zhongshan People's Hospital, Guangdong, China Wuzhou Red Cross Hospital, Xiamen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The health economic benefits of different biomarkers for nasopharyngeal carcinoma To explore the overall survival rate, progression free survival rate and health economic benefits of NPC screening using different biomarkers 5 years
Other New screening strategy of nasopharyngeal carcinoma screening Comprehensive analysis of the performance of different biomarkers and their combination in the screening of nasopharyngeal carcinoma 5 years
Primary Sensitivity and specificity of different EBV associated biomarkers To compare the sensitivity and specificity of different EBV associated biomarkers for NPC 5 years
Primary Positive and negative predictive values of different EBV associated biomarkers To compare the positive and negative predictive values of different EBV associated biomarkers for NPC 5 years
Secondary Number needed to screen to identify one nasopharyngeal carcinoma To compare the number of participants needed to screen identify one nasopharyngeal carcinoma for different biomarkers 5 years
Secondary Early diagnosis rate of nasopharyngeal carcinoma To compare the early diagnosis rate of different biomarkers for nasopharyngeal carcinoma 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05979961 - Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT06055816 - Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05547971 - Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
Not yet recruiting NCT05020925 - SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 1/Phase 2
Not yet recruiting NCT04547088 - Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT04548271 - Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02795169 - Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02801487 - Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02569788 - Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Completed NCT02237924 - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02044562 - Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients N/A
Terminated NCT01694576 - NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation Phase 2
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01271439 - Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma Phase 2
Completed NCT00535795 - Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Phase 3
Completed NCT00379262 - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Phase 3
Completed NCT03398980 - Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy N/A
Completed NCT01309633 - Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) Phase 2